Amneal Pharmaceuticals press release (AMRX): Q1 Non-GAAP EPS of $0.27 beats by $0.10. – Revenue of $722.52M (+3.9% Y/Y) beats by $5.74M. – Adjusted EBITDA in the first quarter of 2026 was $202 million, an increase of 19% compared to the first quarter of 2025, reflecting
Beats Amneal Pharmaceuticals Top-line and Bottom-line Estimates; Reaffirms FY26 Outlook
Amneal Pharmaceuticals press release (AMRX): Q1 Non-GAAP EPS of $0.27 beats by $0.10. - Revenue of $722.52M (+3.9% Y/Y) beats by $5.74M. - Adjusted EBITDA in the first quarter of 2026 was $202 million, an increase of 19% compared to the first quarter of 2025, reflecting